EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Incidence of significant prostate cancer after negative MRI and systematic biopsy in the FUTURE trial

Leonie Exterkate iD, Olivier Wegelin, Jelle O Barentsz, Marloes G van der Leest, J Alain Kummer, Willem Vreuls, Peter C de Bruin, J Alfred Witjes, Harm H E van Melick, Diederik M Somford iD

BJU International · 2023-03 · 131 (3) · 313-320

DOI: 10.1111/bju.15876 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift BJU International, online erschienen am 11.09.2022. Verfasst von Leonie Exterkate und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To assess the proportion of clinically significant (cs) prostate cancer (PCa) found during follow‐up in patients with negative systematic biopsy (SB) followed by non‐suspicious multiparametric magnetic resonance imaging (mpMRI) and persistent clinical suspicion of PCa compared to the general population. Patients and Methods A prospective study in a subgroup of patients from a multicentre randomized controlled trial was conducted between 2014 and 2017, including 665 men with prior negative SB with a persistent elevated prostate‐specific antigen and/or suspicious digital rectal examination undergoing mpMRI. All patients with negative SB and Prostate Imaging‐Reporting and Data System (PI‐RADS) ≤2 on mpMRI entered biochemical follow‐up. Follow‐up data until December 2021 were collected by reviewing institutional hospital records and the Dutch Pathology Registry (PALGA). The primary outcome was the observed number of csPCa (Gleason ≥3 + 4/International Society of Urological Pathology grade group ≥2) cases during follow‐up compared to the expected number in the general population (standardized incidence ratio [SIR]).

Results

In total, 431 patients had non‐suspicious mpMRI and entered biochemical follow‐up. After a median (interquartile range) follow‐up of 41 (23–57) months, 38 patients were diagnosed with PCa, of whom 13 (3.0%) had csPCa. The SIR for csPCa was 4.3 (95% confidence interval 2.3–7.4; total excess of eight cases). A higher risk of a positive biopsy for (cs)PCa based on the European Randomized Study of Screening for Prostate Cancer risk calculator and a suspicious repeat MRI (PI‐RADS ≥3) were significant predictive factors for csPCa.

Conclusion

After negative prior biopsy and non‐suspicious mpMRI the risk of csPCa is low. However, compared to the general population, the risk of csPCa is increased despite the high negative predictive value of mpMRI. More research focusing on biochemical and image‐guided risk‐adapted diagnostic surveillance strategies is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsMaleHumansMagnetic Resonance ImagingProspective StudiesIncidenceBiopsyImage-Guided BiopsyRetrospective Studies

Stichwörter der Autor:innen

#PCSM#ProstateCancer#urooncdiagnostic surveillancefollow-upmultiparametric magnetic resonance imagingprostate biopsyprostate cancer

Autor:innen und Institutionen

  • Department of Urology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.
  • Department of Urology, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands.
  • Department of Radiology and Nuclear Medicine, Radboudumc, Nijmegen, The Netherlands.
  • Department of Pathology, St. Antonius Hospital, Nieuwegein/Utrecht, The Netherlands.
  • Department of Pathology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.
  • Department of Urology, Radboudumc, Nijmegen, The Netherlands.

ORCID-Profile: Leonie Exterkate, Diederik M Somford

Zitieren

APA

Exterkate, L., Wegelin, O., Barentsz, J. O., van der Leest, M. G., Kummer, J. A., Vreuls, W., de Bruin, P. C., Witjes, J. A., van Melick, H. H. E., & Somford, D. M. (2023). Incidence of significant prostate cancer after negative MRI and systematic biopsy in the FUTURE trial. BJU International, 131(3), 313-320. https://doi.org/10.1111/bju.15876

Vancouver

Exterkate L, Wegelin O, Barentsz JO, van der Leest MG, Kummer JA, Vreuls W, et al. Incidence of significant prostate cancer after negative MRI and systematic biopsy in the FUTURE trial. BJU International. 2023;131(3):313-320. doi:10.1111/bju.15876

BibTeX
@article{Exterkate2023,
  author = {Exterkate, Leonie and Wegelin, Olivier and Barentsz, Jelle O and van der Leest, Marloes G and Kummer, J Alain and Vreuls, Willem and de Bruin, Peter C and Witjes, J Alfred and van Melick, Harm H E and Somford, Diederik M},
  title = {Incidence of significant prostate cancer after negative MRI and systematic biopsy in the FUTURE trial},
  journal = {BJU International},
  year = {2023},
  volume = {131},
  number = {3},
  pages = {313--320},
  doi = {10.1111/bju.15876}
}
Kostenlos starten →